Sometime soon, it’s entirely possible that Pfizer will buy AstraZeneca for a price that would exceed the gross national product of all but about 50 countries worldwide. Should that happen, a long, complicated process will unfold. Pfizer (NYSE: PFE) will talk about bringing together two titans with franchises in big fields like oncology, inflammation, and cardiovascular disease, while its financial people tout massive tax savings. Shareholders of AstraZeneca (NYSE: AZN) will walk away with a lot of extra cash and perhaps stock.
Help employers find you! Check out all the jobs and post your resume.
